Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The 56 Point TA; Charts With an Attitude -- Ignore unavailable to you. Want to Upgrade?

To: Doug R who wrote (13390)	3/16/1998 7:40:00 AM
From: Jonathan Lebed	Respond to of 79270

PWSP JUST MADE A NEW PICK! Their pick has really bottomed out,, members.tripod.com Jon

To: Doug R who wrote (13390)	3/16/1998 12:24:00 PM
From: Kim	Respond to of 79270

Hi Could you please peek at MVSI it had based awhile at 6 ish and has been rising slowly on mediocre to low volume(today vol is geater) Bluestone is supposedly going to work with them on certain fundamental, i.e. selling mvs and giving a recommendation... any comments would be greatly appreciated by us long term holders TIA kim

To: Doug R who wrote (13390)	3/16/1998 12:33:00 PM
From: Michael L.	Read Replies (1) \| Respond to of 79270

Whoever is interested in biotech, here is some news: Follow Five-Year Plan Successful Investor Says SAN DIEGO--(BUSINESS WIRE)--March 12, 1998--If you want to catch the next wave in biotechnology, follow a five-year plan says a successful long-time biotech investor. Jerry Larson, a major biotechnology investor and one of the few individual investors regularly invited to institutional conferences, says the waves come every five years. ''I've seen companies lose a chairman and the stock goes up, and I've watched firms declare that drugs work and the stocks go down,'' Larson quipped. ''The sector seems to move every five years, not necessarily for rhyme or reason. That means we may not see broad improvement until 1999.'' Larson, a stock picker, typically owns only 10 biotech stocks. ''Isis (Nasdaq:ISIP - news) is my best value right now. They've got seven products in the clinic and more in development, great technology, patents. These are products they own by themselves, not in partnership, yet look where the stock's trading.'' ISIP trades around 13. Larson's Top Ten in order of preference are: Isis Pharmaceuticals, AXYS Pharmaceuticals (Nasdaq:AXPH - news), Agouron Pharmaceuticals (Nasdaq:AGPH - news), Icos Corp. (Nasdaq:ICOS - news), Alteon (Nasdaq:ALTN - news), Cephalon (Nasdaq:CEPH - news), Sugen (Nasdaq: SUGN - news), Cor Therapeutics (Nasdaq:CORR - news), Gilead Sciences (Nasdaq:GILD - news) and Ligand Pharmaceuticals (Nasdaq:LGND - news). Associate biotech analyst Michael Wood at Hambrecht & Quist hopes good results and drug-approvals propel selected stocks. Wood blames ''a significant number'' of clinical trial failures for sector softness. Sangstat Medical (Nasdaq:SANG - news)--''We expect approval for Cyclosporine in roughly two months and profitability by year's end''--Incyte Pharmaceuticals (Nasdaq:INCY - news) among drug discoverers, and Biochem Pharma (Nasdaq:BCHE - news), which may have approval for its hepatitis B drug in Asia and South America by mid-year, are top picks, Wood said. Two biotech Forums hosted by Informed Investors (www.informedinvestors.com) this weekend will give investors timely insights into picks, pans and trends in the biotech industry. On March 14 at the Mission Valley Radisson from 8am-12:45pm is the 2nd San Diego Informed Investors Biotech Forum. Keynote speaker Michael Murphy of the California Technology Stock Letter will give investors his views on biotech stocks, while executives of Cypros (AMEX:CYP - news), Genta (Nasdaq:GNTA - news), Trega (Nasdaq:TRGA - news), Aurora (Nasdaq:ABSC - news) and Vical (Nasdaq:VICL - news) will give presentations. On March 15 the 4th Informed Investors Bay Area Biotech Forum will be held at the Bay Bridge Holiday Inn at I-80 & Powell Street in Emeryville near San Francisco from 8a-12:45pm. Biotech analyst David Crossen of NationsBanc Montgomery, will give his outlook for biotech. Presenting at the Forum are top executives of Geron (Nasdaq:GERN - news), Gilead Sciences, (Nasdaq:GILD - news), XOMA Corp. (Nasdaq:XOMA - news), Myriad Genetics (Nasdaq:MYGN - news) and Shaman Pharmaceuticals (Nasdaq:SHMN - news). Cost to for either Forum is $15 in advance or $20 at the door and includes a continental breakfast. Call Informed Investors at 800/992-4683. Sets of audiotapes are $25, or $45 for both, plus $3.95 shipping and handling. Informed Investors has featured scores of quality companies and industry experts at its Forums since 1993 and represents individual investors who collectively hold an estimated $1.5 billion in investable assets.